IκBζ: an emerging player in cancer

Marie Willems; Nadège Dubois; Lucia Musumeci; Vincent Bours; Pierre A. Robe

doi:10.18632/oncotarget.11624

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

IκBζ: an emerging player in cancer

Marie Willems, Nadège Dubois, Lucia Musumeci, Vincent Bours and Pierre A. Robe _

PDF | HTML | How to cite

Oncotarget. 2016; 7:66310-66322. https://doi.org/10.18632/oncotarget.11624

Metrics: PDF 2047 views | HTML 5630 views | ?

Abstract

Marie Willems1, Nadège Dubois1, Lucia Musumeci1, Vincent Bours1 and Pierre A. Robe1,2

1 Department of Human Genetics and GIGA Research Center, University of Liège, Liege, Belgium

2 Department of Neurology and Neurosurgery, T&P Bohnenn Laboratory for Neuro-Oncology, Brain Center Rudolf Magnus, University Medical Center of Utrecht, Heidelberglaan, Utrecht, The Netherlands

Correspondence to:

Pierre A. Robe, email:

Keywords: IκBζ, nuclear IκB protein, NF-κB pathway, cancer, perspectives

Received: January 19, 2016 Accepted: August 23, 2016 Published: August 26, 2016

Abstract

IκBζ, an atypical member of the nuclear IκB family of proteins, is expressed at low levels in most resting cells, but is induced upon stimulation of Toll-like/IL-1 receptors through an IRAK1/IRAK4/NFκB-dependent pathway. Like its homolog Bcl3, IκBζ can regulate the transcription of a set of inflamatory genes through its association with the p50 or p52 subunits of NF-κB. Long studied as a key component of the immune response, IκBζ emerges as an important regulator of inflammation, cell proliferation and survival. As a result, growing evidence support the role of this transcription factor in the pathogenesis number of human hematological and solid malignancies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11624

Publication Alerts

Reviews:

IκBζ: an emerging player in cancer

Abstract